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Abstract
Introduction Several monoclonal antibodies (mAbs) have been linked to neuropsychiatric adverse effects in patients, includ-
ing depression and suicidal ideation and behavior.
Objective The aim of this study was to quantify and characterize spontaneously reported adverse drug reactions (ADRs) of 
depression and suicidal ideation and behavior related to mAb users, and to explore a possible association with their mecha-
nism of action.
Methods We included mAb ADRs that were reported in VigiBase, and identified those related to depression and suicidal 
ideation and behavior. Reporting odds ratios (RORs) were estimated for each mAb (bevacizumab as the reference) and 
according to their influence on the immune system (not directly targeting [reference], stimulating, or suppressing). Those 
suppressing the immune system were further divided into their intended indication (auto-immune diseases, cancer).
Results Overall, 2,924,319 ADRs for 44 mAbs were included; 9455 ADRs were related to depression and 1770 were related 
to suicidal ideation and behavior. The association was strongest for natalizumab and belimumab, both for depression (ROR 
5.7, 95% confidence interval [CI] 5.0–6.4; and ROR 5.1, 95% CI 4.2–6.2) and suicidal ideation and behavior (ROR 12.0, 
95% CI 7.9–18.3; and ROR 20.2, 95% CI 12.4–33.0). Those suppressing the immune system showed higher ROR, i.e. 1.9 
(95% CI 1.8–2.0) for depression and 3.6 (95% CI 3.0–4.4) for suicidal ideation and behavior. This finding was only seen for 
mAbs used for treating autoimmune diseases.
Conclusion Depression and suicidal ideation and behavior are seen in patients using mAbs, particularly mAbs used for 
treating autoimmune diseases that suppress the immune system. For interpretation of these data, the indications for use and 
other characteristics require further consideration.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 4-018-00789 -9) contains 
supplementary material, which is available to authorized users.
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Key Points 
Depression and suicidal ideation and behavior are 
reported for monoclonal antibodies (mAbs), espe-
cially for mAbs used for the treatment of patients with 
autoimmune diseases that suppress the immune system.
The present study provides important knowledge for 
future research on the relation between the different 
inflammatory factors and the occurrence of depression 
and suicidal ideation and behavior. Future studies should 
focus on, amongst others, indications for use, and popu-
lation characteristics to characterize and quantify this 
potential risk.
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also been linked to psychiatric disorders. For example, 
approximately 1–10% of patients treated with trastuzumab, 
a human epidermal growth factor receptor 2 inhibitor used 
for the treatment of cancer, develop depression [21]. It 
should be noted that the estimated prevalence of major 
depression among patients with both cancer and autoim-
mune diseases exceed the estimated prevalence in the 
general population [22, 23]. It is therefore challenging to 
differentiate between the underlying disease and the effect 
of treatment.
To date, no studies have, to our knowledge, evaluated 
the potential risk of depression and suicidal ideation and 
behavior for the group of mAbs as a whole. Therefore, 
the first aim of this study was to quantify and character-
ize spontaneously reported adverse drug reactions (ADRs) 
related to depression and suicidal ideation and behavior for 
mAbs. In addition, the association between the mechanism 
of action of the mAb and spontaneously reported ADRs 
of depression and suicidal ideation and behavior will be 
explored.
2  Methods
2.1  Setting and Data Source
VigiBase, the World Health Organization global individ-
ual case safety report (ICSR) database that is maintained 
by the Uppsala Monitoring Centre, was used as the data 
source for this study [24]. As of December 2017, over 
16 million case reports of ADRs have been submitted 
since the start of data collection in 1968. The ICSRs are 
first reported by healthcare professionals and patients to 
more than 120 national pharmacovigilance centers, and 
then transferred to VigiBase. ICSRs contain information 
regarding patient characteristics, suspected drugs, ADRs, 
and additional information relevant to the report, such 
as the reporter type, reporting year, and reporting region 
[24]. Completeness of the ICSRs is variable. ADRs are 
classified according to the Medical Dictionary for Regula-
tory Activities  (MedDRA®), and suspected drugs are clas-
sified according to the Anatomical Therapeutic Chemical 
(ATC) classification.
All reports included in VigiBase until December 2017 in 
which an mAb was the suspected drug were identified. Only 
mAbs that had been authorized by the European Medicines 
Agency (EMA) and/or the US FDA for 3 or more years as of 
December 2017 were included, accounting for a representa-
tive reflection of the ADRs that are reported. Information on 
the regulatory status was retrieved from the publicly avail-
able information on the FDA (http://www.fda.gov) and EMA 
(http://www.ema.europ a.eu) websites.
1 Introduction
In May 2015, the phase III clinical trials investigating 
the efficacy and safety of brodalumab, a monoclonal 
antibody (mAb) against the interleukin (IL)-17 receptor, 
in patients with psoriasis were terminated early by the 
pharmaceutical company [1]. The trigger for this deci-
sion was six reports of completed suicide as adverse 
events in the approximately 5000 patients treated with 
brodalumab in the clinical trial program [2], although the 
evaluation thereof by both the pharmaceutical company 
and regulatory authorities concluded that a causal rela-
tion between the use of brodalumab and suicidal ideation 
and behavior was unlikely [1, 2]. In May 2017, brodalu-
mab was authorized in the European Union based on the 
assessment of the regulatory authorities that the efficacy 
of brodalumab outweighs the risks, including the poten-
tial risk of suicidal ideation and behavior [2]. Despite 
this conclusion, a warning was included in the product 
information to carefully weigh the risks and benefits of 
treatment with brodalumab for patients with a history of 
depression and/or suicidal ideations, and for patients who 
develop these symptoms during treatment. Furthermore, a 
postauthorization safety study was required with a focus 
on serious events of, among others, suicidal ideation and 
behavior. To date, a mechanism through which brodalu-
mab may cause such events is not known. Research in 
animal studies has shown that IL-17, which is blocked 
by brodalumab, can influence neurological function and 
therefore modulate behavior [3–5]; however, this has not 
been studied in humans.
Depression and suicidal ideation and behavior have also 
been reported in clinical trials of other mAbs, such as beli-
mumab, which is used to treat patients with systemic lupus 
erythematosus and targets against B-cell activating factor 
[6]. In addition, the mAbs infliximab, adalimumab, and 
natalizumab have, in case reports, been associated with 
suicidal ideation and behavior [7–11].
The aforementioned mAbs exert their intended effects 
through targeting different (anti-)inflammatory factors. 
During the past decades, the link between psychiatric 
disorders and autoimmune disorders has been extensively 
discussed [12–14]. This link is considered to be partially 
explained by the influence of inflammatory factors on the 
brain. Different meta-analyses have evaluated the contri-
bution of inflammatory factors in the pathophysiology 
of major depression and suicidal ideation and behavior 
[15–20]. These indicate that alterations in both pro-inflam-
matory and anti-inflammatory factors are linked to psy-
chiatric disorders; however, mAbs that have a mechanism 
of action not directly targeting the immune system have 
889Monoclonal Antibodies and Reporting of Depression and Suicidal Ideation and Behavior
2.2  Outcome
Spontaneously reported ADRs related to depression and sui-
cidal ideation and behavior were identified using the Stand-
ardized  MedDRA® Query (SMQ) ‘Depression and suicide/
self-injury (narrow)’  [MedDRA® version 20.1]. SMQs are 
validated and maintained by the Maintenance and Support 
Services Organization and updated with each version of 
 MedDRA® [25]. The SMQ ‘Depression and suicide/self-
injury (narrow)’ contains 36 preferred terms. A distinction 
is made in preferred terms related to depression (n =24) and 
suicide/self-injury (n =12).
2.3  Exposure
The association between the mAb and spontaneously 
reported ADRs of depression and suicidal ideation and 
behavior was defined in two ways. First, exposure was 
defined for the mAbs individually using bevacizumab as the 
reference. Second, mAbs were grouped by their influence on 
the immune system (not directly targeting the immune sys-
tem, suppressing or stimulating the immune system) based 
on the information provided in the product information (see 
electronic supplementary material 1). mAbs suppressing 
the immune system were further stratified according to their 
intended indication based on their ATC code (autoimmune 
diseases or cancer). Information on the influence of mAbs 
on the immune system and their intended indication was 
retrieved from the product information publicly available 
on the FDA and/or EMA websites.
2.4  Data Analysis
Descriptive statistics were used to quantify the reported 
ADRs at the level of the drug–ADR pair. ADRs were strati-
fied by sex (male, female), age (< 18 years, 18–44 years, 
45–64 years, and ≥ 65 years), reporting year (from the first 
reporting year divided into periods of 5 years), reporting 
region (Africa, the Americas, Southeast Asia, Europe, East-
ern Mediterranean, and Western Pacific), and reporter type 
(healthcare professional, consumer, other). The proportions 
of ADRs for depression and suicidal ideation and behavior 
were calculated by dividing the number of depression or 
suicidal ideation and behavior ADRs by the total number of 
reported ADRs within the stratum.
The strength of the association between mAbs and neu-
ropsychiatric effects was expressed as the reporting odds 
ratio (ROR) with 95% confidence intervals (CIs) [26, 27]. 
RORs were estimated for the ADRs related to depression 
and suicidal ideation and behavior separately. For analysis of 
the individual mAbs, bevacizumab was used as the reference 
as it does not directly target the immune system and has been 
widely used for years, and was therefore considered to have 
an established safety profile. For the analysis of the mAbs 
grouped by their influence on the immune system, mAbs 
not directly targeting the immune system were used as the 
reference. In addition, for the subgroup analysis stratified 
by the intended indication, mAbs not directly targeting the 
immune system were used as the reference.
All data were analyzed using SPSS for Windows, version 
24.0 (IBM Corporation, Armonk, NY, USA).
3  Results
In VigiBase, 3,048,884 ADRs were identified for 139 dif-
ferent mAbs as suspected drugs; 124,565 ADRs for 95 
mAbs were excluded because they were reported for mAbs 
that had not been authorized by the FDA and/or EMA for 
3 or more years as of December 2017. The study popula-
tion therefore comprised 44 mAbs (active substances), for 
which a total of 1,048,576 ICSRs were filed, representing 
2,924,319 drug–ADR pairs, of which 9455 (0.32%) were 
related to depression and 1770 (0.06%) were related to sui-
cidal ideation and behavior.
The proportion of suicidal ideation and behavior ADRs 
was comparable between men and women (0.07% and 
0.06%, respectively), whereas the proportion of depression 
ADRs was higher in women compared with men (0.35% 
and 0.27%, respectively) (Table 1). The highest proportion 
of depression and suicidal ideation and behavior ADRs 
was observed in the age range between 18 and 64 years, at 
0.35% and 0.08%, respectively (Table 1). The highest pro-
portion of depression ADRs originated from the Americas 
region (0.36%), followed by the European region (0.17%). 
No regional differences were seen in the proportion of sui-
cidal ideation and behavior ADRs. The proportion of ADRs 
involving depression increased over time, from 0.11% in 
the period between 2000 and 2004, to 0.28% in the period 
between 2015 and 2017, whereas the frequency of suicidal 
ideation and behavior remained at approximately 0.06%. 
Among consumer reports, the proportion of depression 
ADRs was higher (0.44%) than among reports of health-
care professionals (0.23%), whereas for suicidal ideation 
and behavior, the proportion was comparable (0.05% and 
0.07%).
For seven mAbs, no ADRs were reported for depression, 
and for 17 mAbs, no suicidal ideation and behavior ADRs 
were reported; therefore, the ROR could not be estimated 
for these mAbs.
For depression, the association (relative to bevaci-
zumab) was strongest for natalizumab (ROR 5.7, 95% 
CI 5.0–6.4), followed by belimumab (ROR 5.1, 95% CI 
4.2–6.2) (Fig. 1). Furthermore, RORs were calculated for 
different groups of mAbs based on their influence on the 
immune system (Fig. 2). For depression, the association 
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was strongest for mAbs suppressing the immune system 
(ROR 1.9, 95% CI 1.8–2.0) when compared with mAbs not 
directly targeting the immune system. The mAbs suppress-
ing the immune system were further stratified according to 
their intended indication. The results show that the asso-
ciation with depression for mAbs used for the treatment of 
autoimmune diseases was stronger compared with mAbs 
not directly targeting the immune system (ROR 1.96, 95% 
CI 1.84–2.10), whereas for mAbs used for the treatment 
of cancer, this difference was not seen (ROR 0.9, 95% CI 
0.8–1.0). The mAbs stimulating the immune system were 
all indicated for the treatment of cancer and hence were 
not further stratified.
For suicidal ideation and behavior the ROR (relative to 
bevacizumab) was highest for belimumab (20.2, 95% CI 
12.4–33.0) followed by natalizumab (12.0, 95% CI 7.9–18.3) 
(Fig. 3). When grouping the mAbs based on their influence 
on the immune system, the ROR for suicidal ideation and 
behavior was highest for mAbs suppressing the immune sys-
tem (3.6, 95% CI 3.0–4.4) compared with mAbs not directly 
targeting the immune system (Fig. 4). When stratifying the 
mAbs suppressing the immune system by their intended 
indication, the ROR for mAbs used for the treatment of 
autoimmune diseases was higher compared with mAbs not 
directly targeting the immune system (3.8, 95 CI 3.1–4.7), 
whereas for mAbs used for the treatment of cancer, this dif-
ference was not seen (ROR 1.1, 95% CI 0.7–1.5).
4  Discussion
The current study is, to our knowledge, the first to assess the 
potential risk of depression and suicidal ideation and behav-
ior for the group of mAbs as a whole. The most relevant 
finding of this study is that mAb-induced depression and 
Table 1  Characteristics of 
depression, suicidal ideation 
and behavior, and all adverse 
drug reactions reported for the 
monoclonal antibodies
ADRs adverse drug reactions
Depression ADRs (%) Suicidal ideation and 
behavior ADRs (%)
Total (n  = 2,924,319) 9455 (0.32) 1770 (0.06)
Sex
 Male (n  = 889,618) 2423 (0.27) 638 (0.07)
 Female (n  = 1,896,884) 6669 (0.35) 1072 (0.06)
 Unknown (n  = 137,817) 363 (0.26) 60 (0.04)
Age, years
 < 18 (n  = 62,164) 97 (0.16) 61 (0.10)
 18–44 (n  = 516,973) 1830 (0.35) 515 (0.10)
 45–64 (n  = 838,942) 2822 (0.34) 525 (0.06)
 ≥ 65 years (n  = 481,932) 868 (0.18) 98 (0.02)
 Unknown (n  = 1,024,308) 3838 (0.37) 571 (0.06)
Region
 Africa (n  = 3438) 7 (0.20) 1 (0.03)
 The Americas (n  = 2,433,422) 8648 (0.36) 1523 (0.06)
 Southeast Asia (n  = 4372) 2 (0.05) 3 (0.07)
 Europe (n  = 376,078) 640 (0.17) 196 (0.05)
 Eastern Mediterranean (n  = 3252) 5 (0.15) 1 (0.03)
 Western Pacific (n  = 103,757) 153 (0.15) 46 (0.04)
Reporting years
 1995–1999 (n  = 1367) 0 (0) 0 (0)
 2000–2004 (n  = 52,267) 57 (0.11) 5 (0.01)
 2005–2009 (n  = 284,580) 659 (0.23) 183 (0.06)
 2010–2014 (n  = 1,243,659) 4928 (0.40) 782 (0.06)
 2015–2017 (n  = 1,342,446) 3811 (0.28) 800 (0.06)
Reporter
 Healthcare professional (n  = 1,413,828) 3221 (0.23) 991 (0.07)
 Consumer (n  = 1,285,732) 5600 (0.44) 633 (0.05)
 Other (n  = 29,983) 110 (0.37) 32 (0.11)
 Unknown (n  = 194,776) 524 (0.27) 114 (0.06)
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suicidal ideation and behavior seems to be associated with 
certain specific immune modulating properties.
Depression and suicidal ideation and behavior were most 
often reported for the mAbs belimumab and natalizumab. 
When the mAbs were grouped according to their influence 
on the immune system, we found that depression and sui-
cidal ideation and behavior were more frequently reported 
for mAbs suppressing the immune system compared with 
mAbs that do not directly target the immune system. Further 
stratification by intended indication of the mAbs suppressing 
the immune system only showed this difference in mAbs 
used for the treatment of autoimmune diseases. When char-
acterizing the reports, the most marked finding was that the 
proportion of consumer reports related to depression was 
approximately twofold higher compared with healthcare 
professionals.
The discrepancy in the reporting of depression by patients 
compared with healthcare professionals, as found in this 
study, is in line with previous studies showing that patients 
are more likely to report psychiatric ADRs compared with 
healthcare professionals [28, 29]. This may be explained by 
the nature of the events, as these are experienced by patients 
to have a direct impact on quality of life.
Belimumab and natalizumab showed the highest report-
ing of depression and suicidal ideation and behavior relative 
to bevacizumab. For belimumab, the potential risk of depres-
sion was seen in clinical trials and is listed in the product 
information [30, 31]. Furthermore, the pharmaceutical com-
pany is currently performing a study to further character-
ize this potential risk [30]. For natalizumab, studies have 
reported improvement in depression symptoms [32]. How-
ever, natalizumab has also been reported to cause suicidal 
ideation and behavior by inducing peripheral cell-mediated 
inflammation resulting in cytokine secretion (in particular, 
tumor necrosis factor [TNF]-α) [10]. Our study shows a sub-
stantial number of reports for natalizumab, indicating that 
Fig. 1  Reporting odds ratios, 
relative to bevacizumab, 
of depression adverse drug 
reactions for the monoclonal 
antibodies separately. ROR 
reporting odds ratio
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this potential risk should be taken into consideration when 
treating patients with natalizumab. Besides both agents sup-
pressing the immune system, belimumab and natalizumab 
do not share further mechanistic commonalities. Due to the 
limited number of mAbs with more specific mechanistic 
commonalities (e.g. TNFα inhibitors, IL inhibitors), we were 
unable to clearly identify patterns in reporting for mAbs 
with these mechanistic commonalities. As a result, it is not 
possible to indicate if this potential risk should be monitored 
for in the postmarketing phase of new mAbs with a specific 
mode of action.
We also found that depression and suicidal ideation and 
behavior are more frequently reported for mAbs suppressing 
the immune system compared with mAbs that do not directly 
target the immune system. Different meta-analyses showed 
that inflammatory factors play a role in the pathophysiology 
of depression and suicidal ideation and behavior [15–20]. 
In general, it is assumed that patients with depression or 
suicidal ideation and behavior have increased levels of pro-
inflammatory factors compared with healthy subjects. How-
ever, in meta-analyses, alterations in both pro-inflammatory 
and anti-inflammatory factors have been linked to these psy-
chiatric disorders. In addition, the influence of psychiatric 
diseases has been reported for both low and high levels of 
pro-inflammatory factors [33]. The influence exerted by 
inflammatory factors involves a complicated process and full 
understanding of their role is lacking. This makes it chal-
lenging to fully explain the potential influence of mAbs on 
these inflammatory factors. In this study, we showed that 
depression and suicidal ideation and behavior are more fre-
quently reported for mAbs suppressing the immune system 
compared with mAbs that do not directly target the immune 
system. This may be explained by the alterations in the levels 
of inflammatory factors caused by the mAbs.
When the analysis was stratified by the intended indica-
tion of the mAb, the difference seen for mAbs suppress-
ing the immune system was only seen in mAbs used for 
the treatment of autoimmune diseases and not those that 
suppress the immune system and are used for the treat-
ment of cancer. The potential issue of confounding by 
indication should therefore be taken into consideration 
when interpreting these results. As previously described, 
the estimated prevalence of depression for both patients 
with cancer and autoimmune diseases exceeds the esti-
mated prevalence in the general population; however, for 
the main indications of the mAbs suppressing the immune 
system included in our study, the prevalence of depression 
seems comparable. In the populations treated with mAbs 
used for the main autoimmune indications (rheumatoid 
arthritis, multiple sclerosis, Crohn’s disease, psoriasis, and 
systemic lupus erythematosus), the prevalence of depres-
sion is similar and ranges from 20 to 30% [23, 34–37]. The 
main indications for the mAbs used for cancer were hema-
tological malignancies, and the prevalence of depression is 
estimated to be approximately 20% in these patients [38].
The strength of this study is that the reports included 
where retrieved from VigiBase, the largest database con-
taining ICSRs, and were therefore well-suited to obtain 
Fig. 2  Reporting odds ratios, 
relative to monoclonal antibod-
ies not directly targeting the 
immune system, of depression 
adverse drug reactions for 
monoclonal antibodies, grouped 
by their influence on the 
immune system. ROR reporting 
odds ratio
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Fig. 3  Reporting odds ratios, 
relative to bevacizumab, of 
suicidal ideation and behavior 
adverse drug reactions for the 
monoclonal antibodies sepa-
rately. ROR reporting odds ratio
Fig. 4  Reporting odds ratios, 
relative to monoclonal antibod-
ies not directly targeting the 
immune system, of suicidal 
ideation and behavior adverse 
drug reactions for monoclonal 
antibodies, grouped by their 
influence on the immune sys-
tem. ROR reporting odds ratio
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insight into reporting patterns, as well as for ADRs with 
a low reporting frequency, such as suicidal ideation and 
behavior. Furthermore, the analysis was not only per-
formed for the mAbs separately but aimed to explore the 
reporting of depression and suicidal ideation and behavior 
to the mechanism of action of the mAbs.
4.1  Limitations
Several limitations are introduced when using data from 
a spontaneous reporting system. First, we did not have 
information on the number of patients exposed to the 
mAbs and the potential history of psychiatric disorders 
of the patients. In addition, we did not perform a formal 
causality assessment of the reports. Furthermore, the 
willingness to report depression and suicidal ideation and 
behavior may be different between the different disease 
categories. Therefore, the results of this study should be 
considered hypothesis-generating, and additional studies 
are needed to further characterize the potential risk of 
depression and suicidal ideation and behavior in patients 
treated with mAbs.
5  Conclusion
Events of depression and suicidal ideation and behavior are 
reported for mAbs, especially for mAbs that suppress the 
immune system and that are used for the treatment of auto-
immune diseases. This further supports the link between 
inflammatory factors and the occurrence of depression and 
suicidal ideation and behavior. The present study provides 
important knowledge for future research in which, among 
others, the relation between the different inflammatory fac-
tors and the occurrence of depression and suicidal ideation 
and behavior, indications for use, and population charac-
teristics should be studied to characterize and quantify this 
potential risk.
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